Prevention is becoming one of the most important strategic priorities across healthcare, yet many organizations are still grappling with a fundamental question: who actually benefits financially when people stay healthier for longer? As healthcare systems shift toward earlier intervention, chronic disease prevention, and long-term population health management, the economics of prevention are drawing increasing attention from payers, employers, pharma companies, and digital health organizations alike.
At the same time, new models are emerging across GLP-1s, wearable technologies, food-as-medicine programs, longevity platforms, metabolic health, and employer-sponsored prevention initiatives. While interest and investment continue to grow, organizations are still working through how to measure value, align incentives, and sustain programs that often require upfront investment before delivering long-term returns.
This roundtable brings together leaders across healthcare, digital health, pharma, and employer ecosystems to explore the evolving economics of prevention and what it takes to make prevention models scalable, measurable, and commercially sustainable. The discussion will focus on how organizations are evaluating ROI, where value is being captured today, and what incentive structures may shape the next phase of preventive health.
Join us to discuss:
How are payers, employers, and healthcare organizations evaluating the economics of prevention today?
Where are prevention models demonstrating measurable impact across utilization, workforce health, and long-term outcomes?
What incentive structures, reimbursement models, and partnerships are emerging to support scalable preventive health strategies?
